Actavis has over 650 products on the Group’s markets, including more than 30 oncology products acquired through the acquisition of the Romanian oncology business, Sindan, in March 2006.
In addition, the Group has one of the strongest pipelines in the industry with more than 330 projects (approx. 210 molecules) in development and registration.